CENTURY THERAPEUTICS ($IPSC) posted quarterly earnings results for Q4 2025 on Thursday, March 12th. The company reported earnings of -$0.25 per share, beating estimates of -$0.29 by $0.04. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $IPSC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CENTURY THERAPEUTICS Insider Trading Activity
CENTURY THERAPEUTICS insiders have traded $IPSC stock on the open market 11 times in the past 6 months. Of those trades, 3 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IPSC stock by insiders over the last 6 months:
- BRENT PFEIFFENBERGER (President and CEO) has made 2 purchases buying 87,000 shares for an estimated $47,680 and 1 sale selling 32,456 shares for an estimated $14,735.
- CHAD COWAN (Chief Scientific Officer) has made 1 purchase buying 58,060 shares for an estimated $49,252 and 1 sale selling 5,462 shares for an estimated $2,736.
- DOUGLAS CARR (SVP Finance & Operations) has made 0 purchases and 4 sales selling 1,119 shares for an estimated $1,522.
- GREGORY RUSSOTTI (See Remarks) has made 0 purchases and 2 sales selling 1,005 shares for an estimated $1,494.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CENTURY THERAPEUTICS Hedge Fund Activity
We have seen 15 institutional investors add shares of CENTURY THERAPEUTICS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 5,961,631 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,930,630
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 3,538,609 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,520,208
- RENAISSANCE TECHNOLOGIES LLC removed 1,237,700 shares (-47.8%) from their portfolio in Q4 2025, for an estimated $1,231,263
- DAFNA CAPITAL MANAGEMENT LLC added 1,089,354 shares (+63.9%) to their portfolio in Q4 2025, for an estimated $1,083,689
- TANG CAPITAL MANAGEMENT LLC removed 900,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $895,320
- TWO SIGMA INVESTMENTS, LP added 584,470 shares (+64.1%) to their portfolio in Q4 2025, for an estimated $581,430
- ACADIAN ASSET MANAGEMENT LLC added 497,295 shares (+69.1%) to their portfolio in Q4 2025, for an estimated $494,709
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CENTURY THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $IPSC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 01/20/2026
To track analyst ratings and price targets for CENTURY THERAPEUTICS, check out Quiver Quantitative's $IPSC forecast page.
CENTURY THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $IPSC recently. We have seen 2 analysts offer price targets for $IPSC in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $4.0 on 01/20/2026
- Daina Graybosch from Leerink Partners set a target price of $2.0 on 11/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
